Title and Organization:
Dipal Doshi, MBA, is the president and CEO of Entrada Therapeutics, a biotechnology company focused on the treatment of devastating diseases through the intracellular delivery of biologics. Dipal also serves on Entrada’s Board of Directors. Prior to Entrada, he served as the chief business officer for Amicus Therapeutics (FOLD), where he led Amicus’ business and corporate development, global strategy, new product planning, and commercial planning functions. Previously, Dipal was the SVP at Auven Therapeutics, a healthcare private equity fund. He also held corporate development and operating roles at Catalent Pharma Solutions and was a member of Merrill Lynch's Investment Banking Group. Prior to receiving his MBA, Dipal held roles at Eli Lilly and Sapient Corporation (Publicis). He serves as a member of the Board of Directors for the Children's Health Fund. He received a BA from Rutgers University and an MBA from The Wharton School of the University of Pennsylvania. Dipal is a Fellow of the second class of the Health Innovators Fellowship and a member of the Aspen Global Leadership Network.